FORT WORTH, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales volumes averaged approximately 48.6 thousand barrels of crude oil equivalent per day (“MBoe/d”), remaining essentially flat from the same period a year ago after dropping down to one drilling rig in May 2025.Net income was $26.2 million, or $0.19 per diluted share and EB ...

Another quarter’s in the books, and Potbelly (NASDAQ: PBPB ) is once again showing why it’s one of Goulart Restaurant Stocks’ top picks in the fast-casual game.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship w ...

Key Takeaways SoundHound AI's Q2 revenues jumped 217% to $42.68M, beating Wall Street estimates.Automotive division growth includes a major OEM voice assistant integration.Full-year revenue outlook raised to $160M-$178M on new customer gains in China.SoundHound AI, Inc.’s (SOUN) shares have declined 31.7% this year, mainly because of competition from the Chinese artificial intelligence (AI) company DeepSeek, which launched its R1 model, and NVIDIA Corporation’s (NVDA) clear plans to expand in the agentic AI ...

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11 ...

Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025Mature data from the Phase 1b/2 study of palazestrant in combination with ribociclib to be presented at ESMO 2025 Ended the second quarter with $361.9 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Aug. ...

Core Insights - Aquestive Therapeutics announced pivotal progress with the FDA's acceptance of the NDA for Anaphylm, which could become the first oral, sublingual film epinephrine product if approved [2][3] - The company is preparing for a potential U.S. launch in 2026 and is also engaging in regulatory discussions for global expansion in Canada and the EU [2][4] - Financial results for Q2 2025 showed total revenues of $10.0 million, a decrease from $20.1 million in Q2 2024, primarily due to the prior year's one-time revenue recognition [11][14] Regulatory and Product Development - The FDA has accepted the NDA for Anaphylm, with a PDUFA date set for January 31, 2026, and the company is preparing for an Advisory Committee meeting [3][7] - Anaphylm has completed 10 clinical studies with approximately 935 administrations across 379 subjects, addressing the unmet need for non-invasive epinephrine delivery options [3][5] - The company is also advancing AQST-108, a topical gel for alopecia areata, with an anticipated IND submission in Q4 2025 [6] Commercial Strategy - Aquestive is building a commercial launch team for Anaphylm and leveraging existing infrastructure for execution [4] - The company views international markets as critical for long-term strategy and is actively pursuing regulatory meetings in Canada and the EU [4][5] - Anaphylm is positioned to address barriers to epinephrine adoption, such as fear of needles and device complexity, potentially transforming emergency allergy treatment [5] Financial Performance - Total revenues for Q2 2025 increased by $0.3 million, or 3%, year-over-year, excluding the impact of one-time deferred revenue recognition [11] - Manufacturing and supply revenue rose to $9.6 million in Q2 2025 from $8.1 million in Q2 2024, driven by increased Ondif revenues [12] - The net loss for Q2 2025 was $13.5 million, compared to a net loss of $2.7 million in Q2 2024, primarily due to decreased revenues and increased administrative expenses [14][15] Future Outlook - The company expects total revenue for the full year 2025 to be between $44 million and $50 million, with a non-GAAP adjusted EBITDA loss projected between $47 million and $51 million [17] - Cash and cash equivalents were reported at $60.5 million as of June 30, 2025, indicating a stable financial position for ongoing operations [16]

Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North A ...

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025. Financial Highlights for Fiscal Quarter ended June 30, 2025 Revenue of approximately $602.5 million, which represents an increase of approximately 24.7% from the same quarter last year, primarily driv ...

 Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to scientific leadership role Revenue of $26.8 million and $48.8 million for the three and six months ended June 30, 2025, respectivelyGAAP basic EPS: $0.00 and $0.04 for the three and six months ended June 30, 2025, respectivelyPivotal Phase 3 trial of Hydronidon ...

Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA1 for the Second Quarter and Six Months Ended June 30, 2025  Positive Net Income Attributable to Gevo of $2.1 million in the Second QuarterPositive Adjusted EBITDA1 of $17 million in the Second QuarterRevenues Increased $14 million Quarter-Over-QuarterPositive Earnings per Share Attributable to Gevo of $0.01 for the Second QuarterResults Driven by Successful Execution on Low-Carbon Ethanol and Carbon Capture Acquisition, First Sa ...